Pfizer has lagged behind the broader market over the past year, but analysts maintain a cautiously optimistic outlook on the ...

Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

Pfizer's (NYSE:PFE) stock up by 7.7% over the past three months. However, we decided to study the company's mixed-bag of ...

Pfizer (NYSE: PFE) was on top of the world when it came to earnings and stock price performance. This was in early pandemic times, as the company's coronavirus treatment and vaccine generated enormous ...

Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

Pfizer’s adjusted net income margin of 38.2% in Q1’25 was much better than the 31.4% in the prior-year quarter. This led to a 12% y-o-y rise in the bottom line to $0.92 during the quarter ...

PFE’s Stock Performance, Rising Estimates & Attractive Valuation Pfizer’s stock has declined 7.3% so far this year against an increase of 2.4% for the industry.

Pfizer Inc. (NYSE:PFE – Get Free Report)’s share price rose 3.6% on Tuesday following a better than expected earnings announcement. The company traded as high as $23.96 and last traded at $23. ...

Pfizer's dismal stock performance in recent years underscores the challenges the big drugmaker faces. Last year, Pfizer's COVID-19 vaccine Comirnaty generated sales of $5.35 billion.